Crossmark Global Holdings Inc. raised its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,817 shares of the biopharmaceutical company’s stock after buying an additional 1,260 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Bristol-Myers Squibb were worth $2,070,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SFE Investment Counsel raised its stake in Bristol-Myers Squibb by 8.6% during the third quarter. SFE Investment Counsel now owns 16,375 shares of the biopharmaceutical company’s stock valued at $1,017,000 after buying an additional 1,290 shares in the last quarter. Benedict Financial Advisors Inc. raised its stake in Bristol-Myers Squibb by 4.0% during the third quarter. Benedict Financial Advisors Inc. now owns 25,248 shares of the biopharmaceutical company’s stock valued at $1,567,000 after buying an additional 974 shares in the last quarter. Yorktown Management & Research Co Inc raised its stake in Bristol-Myers Squibb by 400.0% during the third quarter. Yorktown Management & Research Co Inc now owns 20,000 shares of the biopharmaceutical company’s stock valued at $1,242,000 after buying an additional 16,000 shares in the last quarter. Hollencrest Capital Management raised its stake in Bristol-Myers Squibb by 176.1% during the fourth quarter. Hollencrest Capital Management now owns 9,604 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 6,126 shares in the last quarter. Finally, Highwater Wealth Management LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $170,000. Hedge funds and other institutional investors own 73.19% of the company’s stock.
Shares of Bristol-Myers Squibb stock opened at $50.98 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. The company has a market cap of $82.10 billion, a PE ratio of 12.81, a P/E/G ratio of 1.60 and a beta of 0.83. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $70.05.
The business also recently declared a quarterly dividend, which was paid on Friday, February 1st. Stockholders of record on Friday, January 4th were given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.22%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date was Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.
Several brokerages have issued reports on BMY. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. BMO Capital Markets upped their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a “market perform” rating in a research note on Friday, November 16th. Societe Generale set a $47.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Wednesday, November 14th. Credit Suisse Group set a $59.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 4th. Finally, ValuEngine cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $60.21.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Story: Is a Roth IRA right for you?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.